Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: March 7, 2007
Subject: Entry into a Material Definitive Agreement regarding Outside Director Compensation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and compensation policy.
Material Changes
The Board of Directors amended the cash compensation policy for outside directors, effective January 1, 2007. The new structure includes:
- Base Retainer: $30,000 annually for Board service.
- Audit Committee: $15,000 annually for members; $30,000 for the chair.
- Compensation Committee: $10,000 annually for members; $20,000 for the chair.
- Nominating and Governance Committee: $5,000 annually for members; $10,000 for the chair.
- Board Chair: $30,000 annual retainer.
The equity portion of compensation (option and restricted stock grants) remains unchanged at current levels.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the implementation of the new compensation policy.
Investor Verification Checklist
- Verify the total number of outside directors to estimate the aggregate annual cash cost of the new policy.
- Confirm the specific committee assignments of current directors to calculate individual compensation packages.
- Review prior filings to compare the new cash retainers against historical compensation levels.
- Check subsequent filings for any further amendments to the equity grant policy.